Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.

Saved in:
Bibliographic Details
Title: Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.
Authors: Pagani O; Geneva University Hospitals, Geneva, Switzerland; University Hospitals, Lugano University, Lugano, Switzerland; Swiss Cancer Institute (formerly SAKK), Bern, Switzerland., Niman SM; International Breast Cancer Study Group Statistical Center, Boston, MA, USA; Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA., Ruggeri M; Program for Young Patients, International Breast Cancer Study Group, a division of ETOP IBCSG Partners Foundation, Bern, Switzerland., Peccatori FA; Fertility and Procreation Unit, Gynecologic Oncology Program, IEO, European Institute of Oncology IRCCS, Milan, Italy., Azim HA Jr; Cairo Cure Oncology Center, Cairo, Egypt., Colleoni M; Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy., Saura C; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain., Shimizu C; Department of Breast and Medical Oncology, Japan Institute of Health Security - National Center for Global Health and Medicine, Toyama, Shinjuku-ku, Tokyo, Japan., Sætersdal AB; Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway., Kroep JR; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands; Dutch Breast Cancer Group, BOOG, Utrecht, the Netherlands., Warner E; Odette Cancer Center, Sunnybrook Health Sciences Center, Toronto, Canada., Amant F; Department of Oncology, KU Leuven and Leuven Cancer Institute, Leuven, Belgium; Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium; Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands., Mailliez A; Department of Medical Oncology, Centre Oscar Lambret, Lille, France., Moore HCF; Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Ruiz-Borrego M; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Hospital Virgen del Rocio Sevilla, Sevilla, Spain., Walshe JM; Cancer Trials Ireland, Dublin, Ireland; Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland., Borges VF; Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, Colorado, USA., Gombos A; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium., Kataoka A; Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan., Rousset-Jablonski C; Department of Surgery, Leon Berard Cancer Centre, Centre Léon Bérard, Lyon, France; INSERM U1290 RESHAPE, Lyon, France; Gynecology and Obstetrics Department, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France., Borstnar S; Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia., Takei J; St Luke's International Hospital, Breast Center, Tokyo, Japan., Lee JE; Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Clinical Research and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea., Saunders C; Department of Surgery, University of Melbourne, Melbourne, VIC, Australia; Royal Melbourne Hospital, Melbourne, VIC, Australia., Bjelic-Radisic V; Breast Unit, Helios University Clinic Wuppertal, University Witten/Herdecke, Wuppertal, Germany; Austrian Breast and Colorectal Study Group (ABCSG), Austria., Susnjar S; Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia., Cardoso F; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, and Advanced Breast Cancer (ABC) Global Alliance Lisbon, Portugal., Klar NJ; New York University Langone's Perlmutter Cancer Center, Breast Cancer Center, New York, NY, USA., Ferreiro T; Soul Reconnect, Barcelona, Spain., Ribi K; International Breast Cancer Study Group (IBCSG), a division of ETOP (European Thoracic Oncology Platform) IBCSG Partners Foundation, Bern, Switzerland; Careum School of Health, Part of the Kalaidos University of Applied Sciences, Zurich, Switzerland., Ruddy KJ; Department of Oncology, Mayo Clinic, Rochester, MN, USA., Kammler R; Translational Research Coordination, International Breast Cancer Study Group, a division of ETOP IBCSG Partners Foundation, Bern, Switzerland., El-Abed S; Breast International Group (BIG), Brussels, Belgium., Viale G; International Breast Cancer Study Group Central Pathology Office, Bern, Switzerland; Department of Pathology and Laboratory Medicine, IEO, European Institute of Oncology, IRCCS, Milan, Italy., Piccart M; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium; Breast International Group (BIG), Brussels, Belgium., Korde LA; Jazz Pharmaceuticals, USA., Goldhirsch A; International Breast Cancer Study Group, Division of ETOP IBCSG Partners Foundation, Bern, Switzerland; IEO, European Institute of Oncology, IRCCS, Milan, Italy., Gelber RD; International Breast Cancer Study Group Statistical Center, Boston, MA, USA; Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA; Frontier Science and Technology Research Foundation, Boston, MA USA; Harvard TH Chan School of Public Health, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Corporate Authors: International Breast Cancer Study Group, POSITIVE Trial Consortium
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 May 28. Date of Electronic Publication: 2026 May 28.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1569-8041
DOI:10.1016/j.annonc.2026.05.699